Jamie A Cesaretti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/619230/publications.pdf

Version: 2024-02-01

51 papers 2,560 citations

32 h-index 49 g-index

52 all docs 52 docs citations

52 times ranked 2244 citing authors

#	Article	IF	CITATIONS
1	Biologically effective dose values for prostate brachytherapy: Effects on PSA failure and posttreatment biopsy results. International Journal of Radiation Oncology Biology Physics, 2006, 64, 527-533.	0.8	221
2	Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implications. International Journal of Radiation Oncology Biology Physics, 2003, 56, 448-453.	0.8	125
3	Genetic Predictors of Adverse Radiotherapy Effects: The Gene-PARE project. International Journal of Radiation Oncology Biology Physics, 2006, 65, 646-655.	0.8	120
4	Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients. Radiotherapy and Oncology, 2016, 121, 431-439.	0.6	98
5	ATM sequence variants and risk of radiation-induced subcutaneous fibrosis after postmastectomy radiotherapy. International Journal of Radiation Oncology Biology Physics, 2006, 64, 776-783.	0.8	95
6	Adjuvant radiotherapy improves overall survival for patients with lymph nodeâ€positive head and neck squamous cell carcinoma. Cancer, 2008, 112, 535-543.	4.1	92
7	Combined modality treatment in the management of high-risk prostate cancer. International Journal of Radiation Oncology Biology Physics, 2004, 59, 1352-1359.	0.8	91
8	Local Control Following Permanent Prostate Brachytherapy: Effect of High Biologically Effective Dose on Biopsy Results and Oncologic Outcomes. International Journal of Radiation Oncology Biology Physics, 2010, 76, 355-360.	0.8	90
9	ATM sequence variants are predictive of adverse radiotherapy response among patients treated for prostate cancer. International Journal of Radiation Oncology Biology Physics, 2005, 61, 196-202.	0.8	88
10	Phase 1 study of concurrent sunitinib and imageâ€guided radiotherapy followed by maintenance sunitinib for patients with oligometastases. Cancer, 2009, 115, 3571-3580.	4.1	88
11	Association of Single Nucleotide Polymorphisms in SOD2, XRCC1 and XRCC3 with Susceptibility for the Development of Adverse Effects Resulting from Radiotherapy for Prostate Cancer. Radiation Research, 2008, 170, 49-59.	1.5	81
12	Possession of ATM Sequence Variants as Predictor for Late NormalÂTissue Responses in Breast Cancer Patients Treated WithÂRadiotherapy. International Journal of Radiation Oncology Biology Physics, 2007, 69, 677-684.	0.8	79
13	Urinary symptom flare following I-125 prostate brachytherapy. International Journal of Radiation Oncology Biology Physics, 2003, 56, 1085-1092.	0.8	74
14	Disease-specific survival following the brachytherapy management of prostate cancer. International Journal of Radiation Oncology Biology Physics, 2006, 64, 810-816.	0.8	72
15	Genome-wide association study identifies a region on chromosome $11q14.3$ associated with late rectal bleeding following radiation therapy for prostate cancer. Radiotherapy and Oncology, 2013, 107, 372-376.	0.6	70
16	TGFB1 Single Nucleotide Polymorphisms Are Associated With Adverse Quality of Life in Prostate Cancer Patients Treated With Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2008, 70, 752-759.	0.8	64
17	125I Monotherapy Using D90 Implant Doses of 180 Gy or Greater. International Journal of Radiation Oncology Biology Physics, 2008, 70, 96-101.	0.8	60
18	Radiation Dose Predicts for Biochemical Control in Intermediate-Risk Prostate Cancer Patients Treated With Low-Dose-Rate Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2009, 75, 16-22.	0.8	60

#	Article	IF	CITATIONS
19	Outcomes for patients with highâ€grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy. BJU International, 2009, 104, 1631-1636.	2.5	60
20	Phase II Trial of Concurrent Sunitinib and Image-Guided Radiotherapy for Oligometastases. PLoS ONE, 2012, 7, e36979.	2.5	59
21	A 2-Stage Genome-Wide Association Study to Identify Single Nucleotide Polymorphisms Associated With Development of Erectile Dysfunction Following Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 85, e21-e28.	0.8	59
22	A Genetically Determined Dose–Volume Histogram Predicts for Rectal Bleeding among Patients Treated With Prostate Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2007, 68, 1410-1416.	0.8	54
23	Acceptability and Preliminary Feasibility of an Internet/CD-ROM-Based Education and Decision Program for Early-Stage Prostate Cancer Patients: Randomized Pilot Study. Journal of Medical Internet Research, 2012, 14, e6.	4.3	51
24	Early use of a phosphodiesterase inhibitor after brachytherapy restores and preserves erectile function. BJU International, 2006, 98, 1255-1258.	2.5	48
25	Young Men Have Equivalent Biochemical Outcomes Compared With Older Men After Treatment With Brachytherapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 77, 1315-1321.	0.8	48
26	Low-dose rate prostate brachytherapy is well tolerated in patients with a history of inflammatory bowel disease. International Journal of Radiation Oncology Biology Physics, 2006, 66, 424-429.	0.8	45
27	Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control. International Journal of Radiation Oncology Biology Physics, 2006, 66, 389-394.	0.8	43
28	Prognostic Significance of 5-Year PSA Value for Predicting Prostate Cancer Recurrence After Brachytherapy Alone and Combined With Hormonal Therapy and/or External Beam Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2009, 74, 753-758.	0.8	42
29	Salvage brachytherapy for recurrent prostate cancer. Brachytherapy, 2014, 13, 53-58.	0.5	41
30	There Is No Correlation Between Erectile Dysfunction and Dose to Penile Bulb and Neurovascular Bundles Following Real-Time Low-Dose-Rate Prostate Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1468-1474.	0.8	39
31	Brachytherapy for the Treatment of Prostate Cancer. Cancer Journal (Sudbury, Mass), 2007, 13, 302-312.	2.0	38
32	Effect of low doseâ€rate prostate brachytherapy on the sexual health of men with optimal sexual function before treatment: analysis at ≥â€S7â€∫years of followâ€up. BJU International, 2007, 100, 362-367.	2.5	36
33	Does Neoadjuvant Hormonal Therapy Improve Urinary Function When Given to Men With Large Prostates Undergoing Prostate Brachytherapy?. Journal of Urology, 2010, 183, 634-640.	0.4	26
34	Assessment of postbrachytherapy sexual function: A comparison of the IIEF-5 and the MSEFS. Brachytherapy, 2007, 6, 26-33.	0.5	21
35	Stereotactic Radiosurgery for Thoracic Malignancies. Annals of Thoracic Surgery, 2008, 85, S785-S791.	1.3	20
36	Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation. BJU International, 2006, 98, 979-981.	2.5	19

#	Article	IF	CITATIONS
37	Update on Prostate Brachytherapy: Long-term Outcomes and Treatment-related Morbidity. Current Urology Reports, 2011, 12, 237-242.	2.2	18
38	Distant and local recurrence in patients with biochemical failure after prostate brachytherapy. Brachytherapy, 2008, 7, 217-222.	0.5	17
39	Effect of Radiotherapy Planning Complexity on Survival of Elderly Patients With Unresected Localized Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 81, 706-711.	0.8	14
40	The influence of stigma on the quality of life for prostate cancer survivors. Journal of Psychosocial Oncology, 2017, 35, 451-467.	1.2	14
41	Do high radiation doses in locally advanced prostate cancer patients treated with 103Pd implant plus external beam irradiation cause increased urinary, rectal, and sexual morbidity?. Brachytherapy, 2010, 9, 114-118.	0.5	13
42	Is seminal vesicle implantation with permanent sources possible? A dose–volume histogram analysis in patients undergoing combined 103Pd implantation and external beam radiation for T3c prostate cancer. Brachytherapy, 2007, 6, 38-43.	0.5	12
43	Prostate cancer: the influence of stigma on quality of life and relationship satisfaction for survivors and their partners. Journal of Psychosocial Oncology, 2019, 37, 350-366.	1.2	11
44	Does prior transurethral resection of prostate compromise brachytherapy quality: A dosimetric analysis. International Journal of Radiation Oncology Biology Physics, 2004, 60, 648-653.	0.8	9
45	Adjuvant Radiation With Modern Techniques is the Standard of Care for Stage III Thymoma. Annals of Thoracic Surgery, 2006, 81, 1180-1181.	1.3	9
46	Radiotherapy planning complexity and survival after treatment of advanced stage lung cancer in the elderly. Cancer, 2009, 115, 4865-4873.	4.1	9
47	Salvage low dose rate brachytherapy for prostate cancer recurrence following definitive external beam radiation therapy. Radiotherapy and Oncology, 2021, 155, 42-47.	0.6	8
48	Long-term outcomes and prognostic factors in patients treated with intraoperatively planned prostate brachytherapy. Brachytherapy, 2013, 12, 120-125.	0.5	5
49	Initial results of a randomized phase III trial of high dose image guided radiation with or without androgen deprivation therapy for intermediate-risk prostate cancer. Cancer Treatment and Research Communications, 2019, 19, 100119.	1.7	1
50	A novel technique of intracavitary 125 lodine brachytherapy for vertebral body metastases. Brachytherapy, 2008, 7, 164-165.	0.5	0
51	SU-GG-T-413: Combined Biological Effective Dose Based Treatment Planning for Low Dose Rate Prostate Brachytherapy and IMRT. Medical Physics, 2008, 35, 2819-2819.	3.0	0